The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use

NCT01821911 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

10500

Enrollment

OTHER_GOV

Sponsor class

Conditions

Rabies Vaccine Allergy
Vaccination Adverse Event
Anti-D Antibodies

Interventions

BIOLOGICAL: Zagreb2-1-1
BIOLOGICAL: Essen

Sponsor

Beijing Center for Disease Control and Prevention